CONDUCTING COMPARATIVE CLINICAL-PHARMACOLOGICAL EVALUATION PHARMACOTHERAPY PREPARATIONS OF BOTULINUM TOXIN A IN CHILDREN WITH CEREBRAL PALSY SYNDROME WITH MARKED SPASTICITY

The original methodology for retrospective clinical studies on the criteria of “efficiency/safety” and pharmacoeconomics on the criteria of “cost/effectiveness”is proposed. The results of a retrospective study of medical records in 169 patients with cerebral palsy, which showed that the use of drugs botulinum toxin type A is an important integral component in the long-term treatment of children with spastic forms of cerebral palsy. Presents the results of pharmacoeconomic analysis of the treatment of the syndrome of spasticity in cerebral palsy when used in the complex treatment of Dysport, Botox and Xeomin.